Highlight Therapeutics

Highlight Therapeutics is a private, clinical-stage biotechnology company focused on developing RNA-based immuno-oncology therapies. The company's main program is BO-112, a synthetic double-stranded RNA that mimics a viral infection, which is designed to be injected directly into a tumor to activate the innate immune system and enhance the efficacy of other cancer treatments, including checkpoint inhibitors.

The company's business model is centered on the research and development of these novel cancer therapies. Highlight Therapeutics aims to partner with larger pharmaceutical companies for late-stage development, commercialization, and marketing of its products. The company's target market is the oncology sector, specifically focusing on patients with solid tumors who are not responding to or have relapsed after treatment with checkpoint inhibitors. By targeting this patient population, the company is addressing a significant unmet medical need in the cancer treatment landscape.

Highlight Therapeutics was founded in 2010 and is based in Paterna, Spain. The company has raised Series B funding and is actively advancing its clinical programs to bring its innovative therapies to market.

Keywords: immuno-oncology, RNA-based therapies, cancer treatment, clinical-stage, biotechnology, solid tumors, checkpoint inhibitors, innate immune system, intratumoral injection, drug development